Description
OR502 is an experimental drug being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is a monoclonal antibody, a type of immunotherapy designed to harness the body's own immune system to fight cancer. Specifically, OR502 targets a protein called LILRB2, which is found on certain immune cells. By blocking LILRB2, OR502 aims to enhance the ability of the immune system to recognize and attack cancer cells. The drug is currently in Phase 1 trials, which means researchers are primarily evaluating its safety, determining the best way to give it (dose), and looking for early signs that it might work. In some trials, OR502 is being tested alone, while in others, it is being combined with other immunotherapy drugs like cemiplimab to see if the combination is more effective. The trials are actively recruiting participants.
Mechanism of Action
OR502 is a fully human IgG1 monoclonal antibody. It specifically targets the LILRB2 protein. LILRB2 is a receptor found on certain immune cells, including T cells and natural killer (NK) cells. Binding of LILRB2 can inhibit the activity of these immune cells, potentially dampening the immune response against cancer. By blocking LILRB2, OR502 aims to release this inhibition, thereby boosting the activity of immune cells and enhancing their ability to target and destroy cancer cells. The specific mechanism is being investigated in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.